» Articles » PMID: 30425103

Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD

Overview
Specialty Nephrology
Date 2018 Nov 15
PMID 30425103
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

CKD is common and frequently complicated with hypertension both predialysis and in ESKD. As a major modifiable risk factor for cardiovascular disease in this high-risk population, treatment of hypertension in CKD is important. We review the mechanisms and indications for the major classes of antihypertensive drugs, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, -adrenergic blocking agents, dihydropyridine calcium channel blockers, thiazide diuretics, loop diuretics, mineralocorticoid receptor blockers, direct vasodilators, and centrally acting -agonists. Recent evidence suggests that -adrenergic blocking agents may have a greater role in patients on dialysis and that thiazide diuretics may have a greater role in patients with advanced CKD. We conclude with sharing our general prescribing algorithm for both patients with predialysis CKD and patients with ESKD on dialysis.

Citing Articles

Peroxiredoxin 5 Acts as a Negative Regulator of the Sodium-Chloride Cotransporter Involved in Alleviating Angiotensin II-Induced Hypertension.

Choi H, Jung I, Kim S Antioxidants (Basel). 2025; 14(1).

PMID: 39857434 PMC: 11761572. DOI: 10.3390/antiox14010100.


Effect of Tissue-derived Angiotensinogen on Kidney Injury and Fibrosis in Obstructive Nephropathy.

Jang H, Noh M, Ha L, Kim J, Padanilam B In Vivo. 2024; 38(5):2107-2114.

PMID: 39187331 PMC: 11363765. DOI: 10.21873/invivo.13672.


Framework of Guidelines for Management of CKD in Asia.

Pollock C, Moon J, Ngoc Ha L, Gojaseni P, Ching C, Gomez L Kidney Int Rep. 2024; 9(4):752-790.

PMID: 38765566 PMC: 11101746. DOI: 10.1016/j.ekir.2023.12.010.


The Possible Effect of β-Blocker Use on the Circulating MMP-2/TIMP-2 System in Patients with Chronic Kidney Disease on Conservative Treatment.

Kopanko M, Zabludowska M, Pawlak D, Sieklucka B, Krupa A, Sokolowska K J Clin Med. 2024; 13(7).

PMID: 38610612 PMC: 11012263. DOI: 10.3390/jcm13071847.


Systemic Inflammatory Response Index (SIRI) is associated with all-cause mortality and cardiovascular mortality in population with chronic kidney disease: evidence from NHANES (2001-2018).

Gu L, Xia Z, Qing B, Wang W, Chen H, Wang J Front Immunol. 2024; 15:1338025.

PMID: 38558798 PMC: 10978803. DOI: 10.3389/fimmu.2024.1338025.